LIDDS Lidds AB

LIDDS enters R&D agreement with potential exclusive, global product license option

LIDDS enters R&D agreement with potential exclusive, global product license option

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that an agreement has been signed with Johnson & Johnson Enterprise Innovation Inc. to develop an oncology product based on the NanoZolid® technology for an undisclosed indication.

“I am pleased that we have signed this exciting collaboration,” said Monica Wallter, CEO of LIDDS. “LIDDS favorable and clinically validated results using the NanoZolid® platform with different types of pharmaceutical substances, forms a bedrock for new and innovative oncology products.”

The flexibility of the NanoZolid® technology offers a possibility to develop controlled and sustained release of many different drugs for local application in cancer tumors which improves its efficacy and provides fewer injections and less side effects for the patients.

 

For more information, please contact:

Monica Wallter, CEO, +46 (0)737 07 09 22, e-mail:

This information is such that LIDDS AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above on March 2, 2021 at 14:50 CET.

LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects for cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North (LIDDS). Redeye AB is the Certified Adviser to LIDDS (+46 (0) 8 121 576 90, email: ) For more information, please visit .



EN
02/03/2021

Underlying

LIDDSLidds AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lidds AB

 PRESS RELEASE
Free
LIDDS LIDDS AB

Report from Extraordinary General Meeting in LIDDS

Report from Extraordinary General Meeting in LIDDS UPPSALA, SWEDEN – LIDDS AB (publ)’s (“LIDDS” or the “Company”) Extraordinary General Meeting was held 11 March 2022 in the Company’s premises in Uppsala. The Extraordinary General Meeting resolved as set out below. Authorisation to issue convertiblesThe Extraordinary General Meeting resolved in accordance with the Board of Directors’ proposal to authorise the Board of Directors to, within the scope of the articles of association, with deviation from the shareholders’ pre-emption rights, on one or several occasions during the period un...

March 11, 2022 1 EN
 PRESS RELEASE
Free
LIDDS LIDDS AB

Kommuniké från extra bolagsstämma i LIDDS

Kommuniké från extra bolagsstämma i LIDDS UPPSALA, SVERIGE – LIDDS AB (publ) (”LIDDS” eller ”Bolaget”) höll den 11 mars 2022 extra bolagsstämma i Bolagets lokaler i Uppsala. Den extra bolagsstämman beslutade enligt nedan. Bemyndigande att emittera konvertiblerDen extra bolagsstämman beslutade i enlighet med styrelsens förslag att bemyndiga styrelsen att inom ramen för gällande bolagsordning, med avvikelse från aktieägarnas företrädesrätt, vid ett eller flera tillfällen intill nästkommande årsstämma, fatta beslut om emission av konvertibler i Bolaget. Sådan emission ska endast kun...

March 11, 2022 1 EN
 PRESS RELEASE
Free
LIDDS LIDDS AB

LIDDS publishes agenda for the company's Capital Markets Day 2022

LIDDS publishes agenda for the company's Capital Markets Day 2022 UPPSALA, SWEDEN – LIDDS AB (publ) announced today the agenda for the Capital Markets Day to be held on March 9, 2022, for investors, analysts and media. Agenda Capital Markets Day 2022 15.00-15.10 Welcome - Nina Herne, CEO15.10-15.45 Presentation of LIDDS company strategy and drug delivery technology - Nina Herne, CEO15.45-16.45 Update on LIDDS pipeline and clinical programs - Johan Harmenberg, CMO16.45-16.55 Break16.55-17.15  Financial update - Jenni Björnulfson, CFO17.15-18.00 Q&A session - Nina He...

March 4, 2022 1 EN
 PRESS RELEASE
Free
LIDDS LIDDS AB

LIDDS publicerar agenda för bolagets kapitalmarknadsdag 2022

LIDDS publicerar agenda för bolagets kapitalmarknadsdag 2022 UPPSALA, Sverige – LIDDS AB (publ) meddelade i dag agendan för den kapitalmarknadsdag som kommer att arrangeras den 9 mars 2022 för investerare, analytiker och media. Agenda Kapitalmarknadsdag 2022 15.00-15.10 Välkomnande - Nina Herne, vd15.10-15.45 Presentation av LIDDS uppdaterade strategi och bolagets drug delivery-teknologi - Nina Herne, vd15.45-16.45 Uppdatering kring LIDDS projektportfölj och kliniska program - Johan Harmenberg, CMO16.45-16.55  Paus16.55-17.15   Finansiell uppdaterin...

March 4, 2022 1 EN
 PRESS RELEASE
Free
LIDDS LIDDS AB

Complement to press release: Notice of Extraordinary General Meeting o...

Complement to press release: Notice of Extraordinary General Meeting of LIDDS AB (publ) In the press release published on February 22, 2022, the appendix with the notice was missing. The notice is attached to this press release, which otherwise corresponds with the previously issued press release. The supplement was submitted for publication on February 24, 2022. Notice of Extraordinary General Meeting in LIDDS AB (publ) The shareholders in LIDDS AB (publ) (reg. no. 556580-2856) (the “Company” or “LIDDS”) are hereby convened to the Extraordinary General Meeting on Friday, 11 March 202...

February 24, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch